Rivaroxaban for cancer-associated venous thromboembolism
A systematic review and meta-analysis protocol
Bo Liang, MD*, Li-Zhi Zhao, MD, Hui-Ling Liao, MD, PhD, Ning Gu, MD, PhD

Abstract
Background: All cancers increase developing venous thromboembolism risk, and VTE is the second-leading cause of death among cancer patients. The anticoagulant drugs are considered to be the optimal treatment for patients with cancer-associated VTE. However, there is still controversy whether rivaroxaban, a new oral anticoagulant, can lead to better outcomes globally.

Methods: We will search PubMed, Web of Science, Cochrane Central Register of Controlled Trials and China National Knowledge Infrastructure for relevant published studies before 1 September, 2019, without any language restrictions. Only published randomized controlled trials that meet the inclusion criteria will be included. Subgroup analysis of the type of cancer, the type of VTE, cancer stage, age, sex, ethnicity, history of smoking and drinking as well as the mean, dose and duration of anticoagulants will be performed.

Discussion: Our study aims to estimate the efficacy and safety of rivaroxaban for patients with cancer-associated VTE and to provide recommendations to key stakeholders.

Trial registration: PROSPERO, October 23, 2019, CRD42019143265, https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=143265.

Abbreviations: CENTRAL = Cochrane Central Register of Controlled Trials, CNKI = China National Knowledge Infrastructure, CVC = central venous catheter, DVT = deep venous thrombosis, PE = pulmonary embolism, RCTs = randomized controlled trials, SVT = splanchnic vein thrombosis, VTE = venous thromboembolism, WOS = Web of Science.

Keywords: cancer-associated venous thromboembolism, protocol, rivaroxaban

1. Introduction
Venous thromboembolism (VTE) refers to a condition in which the blood clots from a vein inappropriately, causing considerable morbidity, mortality and economic burden. It is the third leading vascular diagnosis after heart attack and stroke, affecting, to be estimated, between 300,000 to 600,000 Americans each year. All cancers increase developing VTE risk, especially if the cancer has spread widely, and if it is cancer of the lung, brain, lymphoma, gynecologic system, or gastrointestinal tract, and thrombosis is the second-leading cause of death among cancer patients because of activation of coagulation, use of long-term central venous catheter, thrombogenic effects of chemotherapy and anti-angiogenic drugs. Cancer-associated VTE is a prevalent and life-threatening complication in individuals with cancer, with clinically higher morbidity and mortality, and the complexity of its prevention and treatment is due to the much higher risk of complications, including recurrent VTE and major bleeding, in those patients than others. Medicines that help prevent further blood clots from forming or that dissolve serious vein blockages are the main treatments for VTE besides catheter-assisted thrombus removal and vena cava filter, including anticoagulants, or blood thinners, and thrombolytics. The management of anticoagulant therapy for the treatment of VTE in patients either with a diagnosis of cancer or in whom cancer is clinically suspected has also become a major concern among clinicians and relevant patients, since clinicians should consider the bleeding risk, the type of cancer, and the potential for drug-drug interactions in addition to informed patient preference in determining the most appropriate treatment. The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Cancer-Associated VTE outline strategies to prevent and treat cancer-associated VTE, however, it does not directly point out which medicine benefit more. Rivaroxaban is an anticoagulant and the first orally active direct factor Xa
2. Methods

This protocol adheres to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols statement[18] and the results of this study will be published and shared in an international peer-reviewed journal with reference to the PRISMA guidelines.[19] Ethical approval and patient consent are not required as this study is based on published studies.

2.1. Studies search and selection

Two reviewers (BL and HLL) will search PubMed, Web of Science, Cochrane Central Register of Controlled Trials and China National Knowledge Infrastructure for relevant published studies before 1 September, 2019, without any language restrictions. The subject terms and keywords corresponding to Medical Subject Heading terms will be used to search for eligible studies in the databases as mentioned above. Search strategies in PubMed are shown in Table 1.

We will adopt the methods from the Cochrane Handbook for Systematic Reviews of Interventions to pool the evidence.[20] Eligibility criteria for studies to be included in this study will be reported following the PICOS scheme[21] in Table 2. The participants will be patients diagnosed with cancer-associated VTE regardless of the type of cancer, stage, sex, ethnicity, economic status or education. All anticoagulants for participants will be studied. The primary outcomes are defined as recurrent VTE and adverse bleeding events. The secondary outcomes are defined as the quality of life, complication rate and all-cause mortality. Only randomized controlled trials will be included.

All duplicate searched studies will be removed via EndNote X8 software before 2 reviewers (BL and HLL) independently screen each title and abstract. The full texts of all the possibly eligible studies will be checked independently and in duplicate by the 2 reviewers (BL and HLL). In addition, only the studies that do meet the inclusion criteria described above will be included, neither of the 2 reviewers will be blind to the reasons for exclusion. A third author (LZZ) will make final decisions in contradictory judgements. The fourth reviewer (NG) will oversee the entire studies screening and selection process to ensure the completeness and accuracy. The whole process will be shown in a PRISMA flow chart in detail.

2.2. Data extraction and management

One reviewer (BL) will extract the following data from remaining studies: the information about study characteristics (such as the first author, publication date, country, study design and methodology, follow-up duration, withdrawals and the period of the study), demographic characteristics (including age, sex, ethnicity, history of smoking and drinking, pathology diagnosis or clinical suspect and cancer stage), interventions (types and doses of anticoagulants where applicable) as well as outcomes. If the studies mention other drugs used, this information is also recorded for subsequent drug-drug interaction analysis. For missing data, we will contact the study investigators via email to obtain as complete information as possible. Then another 2 reviewers (LZZ and NG) will check the received data. The final author (HLL) will make final decisions in contradictory cases. Finally, all extracted data will be stored in the predesigned excel spreadsheet.

2.3. Quality assessment

Selected studies will be critically and independently assessed by 2 reviewers (BL and HLL) using a revised Cochrane risk of bias tool for randomized trials—RoB 2 tool.[22,23] The assessments include methods of randomization, treatment allocation, blinding, and other biases.[24] The third author (LZZ) will decide in the case of contradictory assessments of the 2 reviewers (BL and HLL) and the risk of bias in each domain will be assessed as high, low or uncertain, and the results of the evaluation will be shown on the risk of bias graph.
2.4. Data synthesis and analysis

The Review Manager 5.3[22] and Stata 12.0 will be adopted to synthesis and analysis data. The results are likely to be substantially heterogeneous and will be synthesized according to the data type and following Centre for Reviews and Dissemination’s guidance.[21] If the data are highly homogeneous, a meta-analysis will be directly conducted with fixed-effect model. Otherwise, after the random-effect model, subgroup analysis will be performed, if the available data are enough, to identify which study the heterogeneity potentially came from. Depending on the type of extracted data, we may apply subgroup analysis by the type of cancer, the type of VTE, cancer stage, age, sex, ethnicity, history of smoking and drinking as well as the mean, dose and duration of anticoagulants. Moreover, in order to reduce or even eliminate the impact of heterogeneity, we will additionally conduct meta-regression and sensitivity analysis. Lastly, the funnel plot and Egger test will be implemented to assess for publication bias.

3. Discussion

To our knowledge, this study will be the first to focus on rivaroxaban on the treatment of cancer-associated VTE. In this study, we combined National Comprehensive Cancer Network[10] Canadian[7] and French[26] guidelines to broadly define VTE as deep venous thrombosis, pulmonary embolism, central venous catheter related thrombosis, superficial vein thrombosis, and splanchnic vein thrombosis. In recent years, many clinical trials about rivaroxaban and VTE in cancer patients have been carried out. Thus, we can more comprehensively evaluate the safety and efficacy of rivaroxaban on the treatment of cancer-associated VTE. As a therapeutic oral anticoagulant, rivaroxaban is mainly metabolized by CYP3A4 and serves as the substrate of the transporter protein p-glycoprotein. The incidence of bleeding complications or treatment failure is lower than that of traditional drugs, warfarin or other vitamin K antagonists. This study will also compare the 2. In addition, rivaroxaban has relatively few drug or food interactions, and we will also analyze if the data are sufficient.

This protocol was developed using validated tools and processes, yet, there are several noteworthy limitations. First, we might miss studies that are relevant to this review. We strive to minimize this issue by working with a librarian on the search strategy. Second, since many studies do not mention cost, it may be difficult to make an economic assessment.

Nevertheless, we anticipate that this study may highlight gaps in knowledge and provide insights into the treatments for cancer-associated VTE. These findings will also inform future research and key stakeholders in developing interventions more effectively and safely.

Acknowledgments

The many relevant published studies are acknowledged for their support.

Author contributions

BL, HLL and LZZ designed and planned the study. BL and NG wrote the report. All authors have read and approved the final version of the report.

References

[1] Beckman MG, Hooper WC, Critchley SE, et al. Venous thromboembolism: a public health concern. Am J Prev Med 2010;38(4 Suppl):S495–501.
[2] Weycker D, Li X, Wygant GD, et al. Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in U.S. clinical practice. Thromb Haemost 2018;118:1951–61.
[3] Goodin . Introduction. Am J Health-Syst Pharm 2005;62(22 Supple- ment 5):S3–13.
[4] Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006;24:484–90.
[5] Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575–9.
[6] Streiff MB, Holmstrom B, Ashrani A, et al. Cancer-associated venous thromboembolic disease, version 1.2015. J Natl Compr Canc Netw 2015;13:1079–95.
[7] Carrier M, Blais N, Crowther M, et al. Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus. Curr Oncol 2018;25:329–37.
[8] Keuran C, Ald EA, Orlelas J, et al. Antithrombotic therapy for VTE disease: J Thromb Thrombolysis 2013;36:133–40.
[9] Streiff MB, Holmstrom B, Angeleni D, et al. NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018. J Natl Compr Canc Netw 2018;16:1289–303.
[10] Piccini JP, Patel MR, Mahaffey KW, et al. Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opin Investig Drugs 2008;17:925–37.
[11] Bjaersch R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363: 2499.
[12] The EINSTEIN-PE Investigators Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287–97.
[13] Prins MH, Lensing AW. Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism. Thromb J 2013;11:13.
[14] Prins MH, Lensing AW, Bjaersch R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013;11:21–121.
[15] Prins MH, Lensing AW, Brightton TA, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014;1:e37–46.
[16] Young AM, Marshall A, Threlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018;36:JCO201878034.
[17] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. BMJ 2015;349:g7647–7647.
[18] Liberati A, Altman DG, Tetzlaff , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Epidemiol Biostat Public Health 2009;6:1–44.
[19] Higgins JPT, Thomas J, Chandler J, et al. (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester (UK): John Wiley & Sons; 2019.
[20] Centre for Reviews and Dissemination (editors). Systematic Reviews: CRD’s guidance for undertaking reviews in health care. York: University of York; 2009.
[21] Serne JAC, Higgins JPT, Savovic J, et al. (editors). Cochrane Methods. Cochrane Database of Systematic Reviews 2016, Issue 10 (Suppl 1). 2016.
[22] Serne JAC, Savovic J, Page MJ, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898.
[23] Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5929–93.
[24] The Cochrane Collaboration. Review Manager (RevMan). 2014.
[25] Farge D, Durant C, Villiers S, et al. Lessons from French national guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients. Thromb Res 2010;125:5108–16.